In a report released on January 21, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...

Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for ...

Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...